Upcoming Global Medical Conferences to Feature IRIDEX Proprietary MicroPulse™
Durable Clinical Effect, Substantial Economic Benefits Support Global
Opportunity for Tissue-Sparing Solution
MOUNTAIN VIEW, Calif., Sept. 26, 2013
MOUNTAIN VIEW, Calif., Sept. 26, 2013 /PRNewswire/ --IRIDEX (Nasdaq: IRIX)
today announced a number of key international conferences and workshops that
will feature its proprietary MicroPulse Laser Therapy for the treatment of
diabetes and glaucoma related disorders.
The upcoming European Society of Retina Specialists (EURETINA) conference in
Hamburg, Germany will feature an official Instructional Course on the use of
IRIDEX' MicroPulse Therapy for retinal disorders such as those caused by
complications of diabetes. EURETINA is Europe's largest society of retina
MicroPulse is a vision-preserving laser treatment that does not produce the
retinal tissue damage that is often associated with traditional laser
"Independent, physician-sponsored inclusion within these influential
conferences further validates our MicroPulse Laser Therapy, which we believe
is well positioned for the current global trend toward value-based
healthcare," said Will Moore, IRIDEX President and CEO. "The durable clinical
effect combined with the substantial economic benefits for healthcare systems,
support the global market opportunity available for our MicroPulse laser
In addition, to address the comprehensive ophthalmologist opportunity in the
emerging global markets for IRIDEX, there will be a company-sponsored
satellite training meeting at the upcoming European Society of Cataract and
Refractive Surgeons (ESCRS) conference. ESCRS is Europe's leading
organization for cataract and refractive surgeons.
The physician-led training will focus on clinical application of IRIDEX'
MicroPulse technology as a single-versatile solution to address the needs of
comprehensive ophthalmologists in both glaucoma and retina.
"With more than 1,400 global views of IRIDEX' most recent webinar, we are
seeing strong interest from physicians in MicroPulse Laser Therapy as a
durable and economically appealing medical solution for both the glaucoma and
retina markets," added Moore.
"Recent data regarding MicroPulse laser's effectiveness for patients suffering
with glaucoma should prove to be a catalyst for ophthalmologists looking for a
versatile solution for their retina, glaucoma, and comprehensive practices."
The following links are to third party websites not affiliated with IRIDEX.
IRIDEX makes no representations as to the accuracy or completeness of any
information contained therein:
Link to EURETINA Instructional Course – Retinal Applications
Link to ESCRS Satellite Meeting – Glaucoma & Retinal Applications
Link to Glaucoma Webinar for MicroPulse Laser Trabeculoplasty - Glaucoma
About MicroPulse Technology
MicroPulse is a tissue-sparing laser therapy that works by electronically
"chopping" the laser emission into trains of microsecond pulses. This enhances
the physician's ability to more precisely control the laser effects on target
tissues, offering the potential for ocular treatment with less collateral
effects than conventional laser treatments.
IRIDEX Corporation was founded in 1989 and is a worldwide leader in
developing, manufacturing, and marketing innovative and versatile laser-based
medical systems, delivery devices and consumable instrumentation for the
ophthalmology market. We maintain a deep commitment to the success of our
customers, with comprehensive technical, clinical, and service support
programs. IRIDEX is dedicated to a standard of excellence, offering superior
technology for superior results. IRIDEX products are sold in the United States
through both direct and independent sales forces and internationally through a
combination of a direct sales force and a network of approximately 70
independent distributors into over 100 countries. For further information,
visit the Company's website at http://www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Act of 1934, as amended, relating to the Company's MicroPulse
technology and the Company's products relating thereto, including market
adoption of these products and the performance of the technology; and trends
in healthcare spending and healthcare systems. These statements are not
guarantees of future performance and actual results may differ materially from
those described in these forward-looking statements as a result of a number of
factors. Please see a detailed description of these and other risks contained
in our Annual Report on Form 10-K for the fiscal year ended December29, 2012
and our Quarterly Reports on Form 10-Q for the fiscal quarters ended March30,
2013 and June29, 2013, each of which was filed with the Securities and
Exchange Commission. Forward-looking statements contained in this announcement
are made as of this date and will not be updated.
Contact: Company Contact: Jim Mackaness, CFO and COO, 650-940-4700, Investor
Relations Contact: Matt Clawson, Allen & Caron, 949-474-4300,
Press spacebar to pause and continue. Press esc to stop.